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Abstract
The regulation of HIF-1a is considered to be realized by pVHL-mediated ubiquitin-26S proteasome pathway at a post-
transcriptional level. The discovery of a class of small noncoding RNAs, called microRNAs, implies alternative mechanism of
regulation of HIF-1a. Here, we show that miR-20b plays an important role in fine-tuning the adaptation of tumor cells to
oxygen concentration. The inhibition of miR-20b increased the protein levels of HIF-1a and VEGF in normoxic tumor cells;
the increase of miR-20b in hypoxic tumor cells, nevertheless, decreased the protein levels of HIF-1a and VEGF. By using
luciferase reporter vector system, we confirmed that miR-20b directly targeted the 39UTR of Hif1a and Vegfa. On the other
hand, the forced overexpression of HIF-1a in normoxic tumor cells downregulated miR-20b expression. However, HIF-1a
knockdown in hypoxic tumor cells caused the increase of miR-20b. The differential expression of miR-20b has important
biological significance in tumor cells, either enhancing the growth or favoring the survival of tumor cells upon the oxygen
supply. Thus, we identify a novel molecular regulation mechanism through which miR-20b regulates HIF-1a and VEGF and is
regulated by HIF-1a so to keep tumor cells adapting to different oxygen concentrations.
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Introduction
Hypoxia is a common feature in solid tumors as the
consequence of poor tumor vascularization [1–3]. The transcrip-
tion factor hypoxia-inducible factor-1 (HIF-1) is a key regulator
responsible for the induction of genes that facilitate adaptation and
survival of tumor cells from hypoxic microenvironment and confer
the tumor a worse malignant phenotype [4,5]. As a heterodimeric
complex, HIF-1 consists of a hypoxically inducible subunit HIF-1a
and a constitutively expressed subunit HIF-1b. The overexpres-
sion of HIF-1a was found in various types of cancers of both
human and mouse [4,6]. To date, the regulation of HIF-1a by
oxygen is elucidated well. Under normoxia, hydroxylation of two
proline residues and acetylation of a lysine residue of HIF-1a are
mediated by oxygen. Such modifications cause tumor suppressor
von Hippel-Lindau protein (pVHL) to bind and degrade HIF-1a
through ubiquitin-26S proteasome system. Nevertheless, in
hypoxia, the hydroxylation is inhibited by the lack of oxygen,
leading to no pVHL binding and the stability of HIF-1a [4–6].
During tumorigenesis, the hypoxic microenvironment and/or
genetic alteration pVHL may cause a high level of HIF-1a in
cancer cells [7,8], suggesting that HIF-1a is a potential target in
tumor therapy.
The regulation of HIF-1a must be tight in cells in order to
precisely adapt to changes of oxygen supply. In this regard, the
mechanisms of regulating HIF-1a might be delicate and complex.
Although pVHL-mediated degradation of HIF-1a is an important
pathway, phosphorylation of HIF-1a also plays a role by
increasing the transcriptional activity of HIF-1a [9,10]. Moreover,
cytokines, growth factors, and environmental stimuli seem to be
involved in the regulation of HIF-1a under nonhypoxic condition
[11,12]. Besides those, whether other pathway(s) involves the
regulation of HIF-1a remains unclear. Recently, the intense
studies on a class of small noncoding RNAs, called microRNAs
(miRNAs), disclose the regulation of gene expression by miRNAs.
The underlying mechanism involves miRNAs annealing to
inexactly complementary sequences in the 39-UTR of target
mRNAs to suppress translation [13,14]. In this regard, HIF-1a is
possibly regulated by miRNAs. Recently, HIF-1a was reported as
the target of miR-17-92 microRNA cluster in lung cancer cells
[15]. In the present study, we further show a molecular
mechanism involving miR-20b regulating HIF-1a and VEGF
and being regulated by HIF-1a, through which tumor cells adapt
to different oxygen concentrations.
Results
Inverse level of miR-20b and HIF-1a in tumor cells
We predicted the candidate mouse microRNAs of targeting
Hif1a by combinatorial utilization of three different algorithms,
including TargetScan (http://www.targetscan.org/), PicTar
(http://pictar.bio.nyu.edu/), and Sanger microRNA target
(http://microrna.sanger.ac. uk/). On the basis of the obtained
information, we focused our attention on miR-18a, miR-199b,
miR-20b and miR-155. Four murine tumor cell lines from
different tissues, including liver cancer H22, breast cancer 4T1,
prostate cancer RM1 and melanoma B16, were tested here. In
normoxia, miR-18a, miR-199b, miR-20b and miR-155 were
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(Figure 1A). However, compared to the normoxic condition, the
expression of miR-20b, rather than miR-18a, miR-199b and miR-
155, in hypoxia was strikingly decreased (Figure 1A). We also
confirmed such expression pattern of miR-18a, miR-199b and
miR-155 by quantitative RT-PCR (Supporting information,
Figure S1). In addition, we determined miR-20a and miR-106-
363 cluster other members (miR-106a, miR-18b, miR-92-2, and
miR-363), since miR-20a is similar to miR-20b and miR-20b
belongs to miR-106-363 cluster [16]. However, the expressions of
those genes seemed not to be associated with the change of oxygen
concentration (Suupporting information, Figure S2). We then
focused our attention on miR-20b. The analysis by quantitative
RT-PCR showed that miR-20b had 64-fold decrease in hypoxia
(Figure 1B). Nevertheless, inverse to the expression pattern of miR-
20b, the protein level of HIF-1a was very low in normoxia, but
very high in hypoxia (Figure 1C). In addition, hypoxia seemed not
to change HIF-1a mRNA expression of tumor cells, evaluated by
real time RT-PCR (Figure 1D). These data suggested a
relationship between miR-20b and HIF-1a expression.
Among the tested tumor cell lines, H22 cells expressed the most
difference of miR-20b between normoxia and hypoxia. We
therefore validated the above in vitro data in vivo by inoculating
H22 cells to BALB/c mice subcutaneously. When tumors reached
to the size of 969 mm, we tested the expression of miR-20b in
different tumor regions. We found that miR-20b was much lower
in the hypoxic central region and much higher in the normoxic
marginal region (Figure 1E). In parallel, HIF-1a detection showed
much higher in the center and much lower in the margin
(Figure 1E). The low expression of miR-20b in hypoxia was not
due to the tumor necrosis. Most tumor cells in the detected tumor
mass were not stained by trypan blue and the mRNA levels of
either b-actin or GAPDH between central region and marginal
region had no significant difference, evaluated by real time RT-
PCR (data not shown). Furthermore, we performed the immuno-
histochemical assay. As expected, the result showed that the
central tumor tissues were positively stained with anti-HIF-1a
antibody; however, the marginal tumor tissues were stained
negatively (Supporting information, Figure S3). Thus, the
expression miR-20b is inversely relative to the level of HIF-1a
protein in tumor cells, implying that tumor cell HIF-1a might be a
target of miR-20b.
HIF-1a is targeted by miR-20b
To verify that HIF-1a is targeted by miR-20b, a blocking
strategy was adapted here by introducing miR-20b inhibitor to
normoxic H22 tumor cells, which indeed increased the protein
level of HIF-1a (Figure 2A). This was not due to the more
degradation of HIF-1a, since miR-20b inhibitor did not affect the
VHL protein level (Figure 2A), which binds and degrades HIF-1a.
On the other hand, the increase of miR-20b level of hypoxic
tumor cells by transfecting miR-20b effectively decreased HIF-1a
protein level (Figure 2B). Similarly, The VHL protein level was not
altered (Figure 2B). In both cases, neither miR-20b inhibitor nor
miR-20b affected the mRNA of HIF-1a (Figure 2C), suggesting
that HIF-1a is a target for miR-20b. To confirm the direct
interaction, a reporter vector system was used here. Transfection
of HIF-1a 39-UTR-containing luciferase reporter vector into
CHO cells resulted in the decent fluorescence production.
Figure 1. Expression of miR-20b is reversely correlated with
HIF-1a level in tumor cells. (A) The expressions of miR-18a, 155, 20b
and 199b in tumor cell lines were detected by RT-PCR in normoxia (20%
oxygen) or hypoxia (1% oxygen). (B) The detection of miR-20b in tumor
cell lines by real time RT-PCR. The miR-20b level in the hypoxia groups
was designated as 1. (C and D) The expression of HIF-1a in tumor cell
lines was detected by Western blot (C) or real time RT-PCR (D). (E)
Expressions of miR-20b and HIF-1a in different tumor regions. 1610
5
H22 tumor cells were inoculated subcutaneously into mice. When
tumor size was .969 mm, the central and marginal regions of tumor
tissues were used for miR-20b and HIF-1a detection by RT-PCR and
Western blot, respectively. Data from three tumor tissues were
presented in this figure.
doi:10.1371/journal.pone.0007629.g001
Figure 2. HIF-1a is targeted by miR-20b. (A) miR-20b inhibitor
increased HIF-1a protein in normoxic H22 cells. miR-20b inhibitor or
control oligonucleotide was transfected into normoxic H22 cells. 48 hr
later, the cells were used to detected HIF-1a and VHL proteins by
Western blot. (B) miR-20b decreased HIF-1a protein in hypoxic H22
cells. miR-20b or control oligonucleotide was transfected into hypoxic
H22 cells. 48 hr later, the cells were used to detect HIF-1a and VHL
proteins by Western blot. (C) miR-20b inhibitor or miR-20b did not
affect the mRNA levels of HIF-1a. The cells of above (A) and (B) were
used for real time RT-PCR to detect HIF-1a mRNA expression. (D) miR-
20b targeted 39-UTR of HIF-1a mRNA. The specificity of miR-20b to 39-
UTR of HIF-1a mRNA was identified as described in Methods.* ,P,0.01,
compared with HIF-1a 39-UTR group.
doi:10.1371/journal.pone.0007629.g002
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resulted in a significant decrease of luciferase activity (Figure 2D).
Thus, miR-20b directly targets 39-UTR of HIF-1a.
miR-20b is downregulated by HIF-1a
The differential expression of miR-20b between normoxia and
hypoxia raised the question of how miR-20b was downregulated in
hypoxic tumor cells. To explore the underlying mechanism, we
hypothesized that miR-20b was regulated by HIF-1. To test this,
HIF-1a was forcedly overexpressed in H22 tumor cells by the
transfection of its expressing vector (Figure 3A). As a result, the
forcedly expressed HIF-1a caused the decrease of miR-20b in
normoxia (Figure 3B). Meanwhile, by a comparable approach, we
silenced HIF-1a expression in hypoxic tumor cells using HIF-1a
siRNA (Figure 3C). As expected, the decrease of HIF-1a resulted
in the increase of miR-20b in hypoxic tumor cells (Figure 3D). In
addition, we transfected VHL siRNA to normoxic tumor cells to
increase the HIF-1a protein level (Figure 3E). Under such
condition, the miR-20b level was also reduced (Figure 3F). Taken
together, these data suggested that HIF-1a downregulates miR-
20b expression in tumor cells.
miR-20b regulating VEGF further tunes tumor cells to
adapt to the alteration of oxygen concentration
Previous study has reported that miR-20b is a putative regulator
of VEGF [17], the pivotal angiogenic factor in response to
hypoxia. Here, we further hypothesized that VEGF was targeted
by miR-20b thus to additionally tune tumor cells to adapt to the
alteration of oxygen concentration. To test this, we performed the
in vitro assay as described above (Figure 2). Under normoxic
condition, the decrease the activity of miR-20b by transfecting
miR-20b inhibitor resulted in the upregulation of VEGF protein
(Figure 4A); under hypoxic condition, the increase miR-20b level
by transfecting miR-20b however downregulated VEGF protein
(Figure 4B). Nevertheless, the mRNA level of VEGF was not
affected by either miR-20b inhibitor or miR-20b (Figure 4C).
Moreover, cotransfection of miR-20b and VEGF 39-UTR-
containing luciferase reporter vector into CHO cells resulted in
a significant decrease of fluorescence intensity (Figure 4D),
suggesting that miR-20b may directly targets 39-UTR of VEGF.
Thus, the regulation of VEGF by miR-20b may further tune
tumor cells to adapt to the alteration of oxygen concentration.
Roles of miR-20b in tumor cells
miR-20b has been reported to accumulate in tumor cells and
speculated to have an oncogenic role [18,19]. Here, we further
explored the biological significance of miR-20b in tumor cells
based on the above study. Under normoxic condition, tumor cells
have the capacity of vigorous proliferation and high expression of
miR-20b, implying a possible role of miR-20b in tumor cell
growth. To verify this, miR-20b inhibitor was transfected into
normoxic H22 tumor cells to block the function of miR-20b. As a
result, tumor cell growth was retarded significantly (Figure 5A).
However, this retardation was rescued by the cotransfection of
HIF-1a siRNA (Figure 5A), suggesting that miR-20b maintains
tumor cell growth through its regulation of HIF-1a. In addition,
the VHL knockdown also dampened H22 cell growth significantly
(Figure 5A). Nevertheless, the further increase of miR-20b level in
normoxic H22 tumor cells by the transfection of miR-20b seemed
to accelerate tumor cell growth but not significantly (Figure 5A).
miR20b was downregulated in tumor cells in hypoxia. We then
further asked whether the decrease of miR-20b contributed to a
more malignant phenotype of cancer cells, such as the enhanced
resistance to apoptosis, the feature of HIF-1a in tumor. To verify
this, miR-20b inhibitor was transfected to normoxic H22 tumor
cells. 24 hr later, the cells were treated with UV irradiation or
chemodrug mytomycin C. The flow cytometric result showed that
inhibition of miR-20b increased the apoptosis resistance of tumor
cells, compared to the control (Figure 5B). Nevertheless,
cotransfection of HIF-1a siRNA completely abolished the effect
of miR-20b inhibitor (Figure 5B), suggesting that the decrease of
Figure 3. miR-20b is downregulated by HIF-1a. (A and B) HIF-1a
decreased miR-20b expression in normoxic H22 cells. HIF-1a vector or
mock vector was transfected into normoxic H22 cells. 72 hr later, the
cells were used for HIF-1a analysis by Western blot (A) and miR-20b
analysis by RT-PCR and real time RT-PCR (B). (C and D) HIF-1a siRNA was
transfected into hypoxic H22 cells. 72 hr later, the cells were used for
HIF-1a analysis by Western blot (C) and miR-20b analysis by RT-PCR and
real time RT-PCR (D). (E and F) VHL siRNA was transfected into normoxic
H22 cells. 72 hr later, the cells were used for VHL and HIF-1a analysis by
Western blot (E) and miR-20b analysis by RT-PCR and real time RT-PCR
(F).
doi:10.1371/journal.pone.0007629.g003
Figure 4. VEGF is targeted by miR-20b. (A) miR-20b inhibitor
increased VEGF protein in normoxic H22 cells. miR-20b inhibitor or
control oligonucleotide was transfected into normoxic H22 cells. 48 hr
later, the cells were used to detected VEGF expression by Western blot.
(B) miR-20b decreased VEGF protein in hypoxic H22 cells. miR-20b or
control oligonucleotide was transfected into hypoxic H22 cells. 48 hr
later, the cells were used to detect VEGF expression by Western blot. (C)
miR-20b inhibitor or miR-20b did not affect the mRNA levels of VEGF.
The cells of above (A) and (B) were used for real time RT-PCR to detect
VEGF mRNA expression. (D) miR-20b targeted 39-UTR of VEGF mRNA.
The specificity of miR-20b to 39-UTR of VEGF mRNA was identified as
described in Methods.* ,P,0.01, compared with VEGF 39-UTR group.
doi:10.1371/journal.pone.0007629.g004
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through increasing the HIF-1a level. In line with these data, miR-
20b inhibitor transfection could affect Bcl-2 family gene
expression, including upregulation of Bcl-xL and downregulation
of Bax in normoxic H22 tumor cells (Figure 5C). Finally, we tested
the role of miR-20b in hypoxia. Normoxic H22 cells were
transfected with miR-20b. 24 hr later, 1610
6 cells were cultured
in hypoxia for 12 h for apoptosis detection by flow cytometry. The
result showed that miR-20b transfection significantly increased the
proportion of apoptotic cells, compared to control (Figure 5D). In
addition, by combinatorial utilization of different algorithms, such
as TargetScan, PicTar, and Sanger microRNA target, we
searched all the candidate target genes for miR-20b. The result
showed that Bcl-xL and Bax were not in the list of candidate
genes, suggesting miR-20b indirectly regulating these genes.
Taken together, these data suggested that HIF-1a-mediated
downregulation of miR-20b is required for H22 cells to adapt
the hypoxia.
Discussion
The current concept on the adaptive responses to changes in
tissue oxygenation is mainly formed from the study on pVHL-
mediated degradation of HIF-1a. Here, we provide alternative
mechanism that a single microRNA, miR-20b, by virtue of its
differential expression in normoxic and hypoxic microenviron-
ment, can finely tune the expressions of HIF-1a and VEGF
in tumor cells, making them to adapt to different oxygen
concentrations.
microRNAs are endogenous non-coding small RNAs of 19–23
nucleotides in length. The biological functions of microRNAs are
involved in numerous cellular processes, including proliferation,
differentiation, metabolism, and motility [20–22]. Coincidently, all
these cellular processes can also be influenced by a transcription
factor HIF-1 [23,24], implying possible connection of HIF-1 and
microRNAs. HIF-1 activity is controlled by the von Hippel-
Lindau tumor suppressor protein (pVHL), a recognition compo-
nent of the E3 ubiquitin ligase. Under normoxic condition, pVHL
binds hydroxylated proline residues within HIF-1a and thereby
targets HIF-1a to the 26S proteasomal degradation system (4–6).
However, during hypoxia, proline hydroxylases are inactive and
can not catalyze the hydroxylation of proline residues of HIF-1a,
leading to the accumulation of HIF-1a in the cell. Besides this
classical regulation machinery, in the present study, we addition-
ally demonstrate that HIF-1a and VEGF is regulated by miR-20b
in tumor cells. Intriguingly, miR-20b is also regulated by HIF-1a;
VEGF can be transcriptionally activated by HIF-1 [25]. Such
multiple regulation relationship among miR-20b, HIF-1a and
VEGF therefore keep tumor cells to adapt different oxygen
concentration for survival.
HIF-1a is a master regulator of oxygen homeostasis [4].
Unusually, its response to oxygen alteration happens at the protein
level rather than mRNA level. The reason maybe is that the cells
can immediately translate the preexisted mRNA into the protein
so to adapt the hypoxia promptly. On the other hand, the
degradation of HIF-1a protein through pVHL-mediated pathway
is also extremely rapid with a half-life estimated to be less than 5
minutes [4]. Such regulation model for HIF-1a is efficient but too
rigid in some physiological conditions. For instance, the formation
of hypoxia in tissues such as embryo or tumor is a gradual process.
Therefore, to reconcile this, a complementary mechanism may be
required. Our findings of the reciprocal regulation of miR-20b and
HIF-1a may be such a paradigm. Interestingly, VEGF is also
targeted by miR-20b directly. Based on these findings, we propose
that miR-20b cooperates with pVHL-mediated degradation
pathway to effectively repress HIF-1a in normoxia. In order to
adapt the gradual onset of hypoxia, inactivation of pVHL pathway
is an initial response, which ceases the degradation of HIF-1a and
leads to the increase of HIF-1a protein. However, to further
increase of HIF-1a and VEGF proteins, tumor cells have to
remove the inhibition of miR-20b on HIF-1a and VEGF by
downregulating miR-20b. Such regulation model confers tumor
cells to sense precisely the alteration of oxygen by the dynamic
equilibrium between miR-20b and HIF-1a.
miR-20b has been reported to accumulate in tumor cells and
might play an oncogenic role [18,19]. Beyond consistence with
these reports, our data here at least partially elucidate the
mechanism underlying miR-20b-promoting tumorigenesis. We
confirm the differential expression of miR-20b in different tumor
regions in a mouse liver cancer model. Such differential expression
of miR-20b may have different roles in tumor cells. High
expression of miR-20b favors tumor cell growth in normoxia;
low expression of miR-20b inhibits tumor cell growth but confers
tumor cell more resistance to apoptosis in hypoxia. Although we
show that the down-regulated miR-20b leads to an increase in the
levels of the anti-apoptotic factor, BcL-xL and a decrease in the
levels of the pro-apoptotic factor, Bax, the informatics analysis
Figure 5. Differential expression of miR-20b affects different
aspects of tumor cells. (A) miR-20b was required for H22 cell growth.
H22 cells were transfected with miR-20b inhibitor or miR-20b inhibitor +
HIF-1a siRNA or miR-20b or VHL siRNA or control oligonucleotide for
24 hr. Then the cells were seeded in 96-well plate (5610
3 per well) for
48 h in normoxia. The proliferation assay was performed with MTT Cell
Proliferation Kit (Roche Diagnostics, IN) according to the manufacturer’s
instructions. *, P,0.05, compared with control. (B) Downregulation of
miR-20b enhanced the resistance to apotosis. H22 cells were
transfected with miR-20b inhibitor or miR-20b inhibitor + HIF-1a siRNA
for 24 hr. Then the cells (1610
6) were irradiated by UVB (200 J/m
2)o r
treated with mitomycin C (MMC, 10 mg/ml)for 12 h. The cells were
stained with PE-Annexin V and 7-AAD for apoptotic analysis by flow
cytometry. *, P,0.05, compared with control. (C) Analysis of the mRNA
expressions of Bcl-2, Bcl-xL, Bax and Bad genes. H22 cells were
transfected with miR-20b inhibitor or miR-20b inhibitor + HIF-1a siRNA
for 72 hr. The cells were used for the analysis of gene expression by real
time RT-PCR. *, P,0.05, compared with control. (D) Normoxic H22 cells
were transfected with miR-20b for 24 hr. Then the cells were cultured
under hypoxic condition for 12 h, and stained with PE-Annexin V and 7-
AAD for apoptotic analysis by flow cytometry. *, P,0.05, compared with
control.
doi:10.1371/journal.pone.0007629.g005
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for miR-20b. Considering the regulation of apoptosis genes by
HIF-1a [26–29], the regulation of apoptosis genes by miR-20b
may be ascribed to the reciprocal regulation of miR-20b and
HIF-1a.
VEGF is one of the most potent stimulators of angiogenesis by
stimulating the proliferation and migration of vascular endothelial
cells [30–32]. In a rapidly growing tumor, the increased diffusion
distances between the blood vessels and the oxygen-consuming
cells [33,34] lead to the decrease of oxygen delivery and local
hypoxia, which trigger the upregulation of VEGF in an effort to
ameliorate the hypoxic state. Regardless of the important role of
VEGF in tumor hypoxia, our data show that miR-20b
downregulates VEGF expression in tumor cells. Thus, the
accumulation of miR-20b in tumor cells [18,19] raises the
question of how tumor cells adapt the hypoxia when the
expression of VEGF is inhibited. A possible reason is that tumor
stromal cells may act as the cellular source of VEGF. On the other
hand, the downregulation of miR-20b may upregulate VEGF
expression in tumor cells, which impairs the inhibitory effort on
tumor cells by the decrease of miR-20b. Therefore, although our
findings and others suggest that miR-20b may be a potential target
in tumor therapy, the combination of targeting miR-20b and
VEGF might be a better choice.
Materials and Methods
Ethics statement
All animal work was conducted according to relevant national
and international guidelines. For details please refer to subsection
entitled Animals and cell lines.
Animals and cell lines
BALB/c mice, 6 to 8-week-old, were purchased from Center of
Medical Experimental Animals of Hubei Province (Wuhan,
China) for studies approved by the Animal Care and Use
Committee of Tongji Medical College. Mouse tumor cell lines
H22 (hepatocarcinoma), 4T1 (breast cancer), RM1 (prostate
cancer), and B16 (melanoma) were purchased from the American
Type Culture Collection (ATCC, Manassas VA) and China
Center for Type Culture Collection (CCTCC, Wuhan, China),
and cultured according to their guidelines. For hypoxic experi-
ments, cells were incubated in a hypoxic incubator. The
atmosphere was maintained at 1% O2, 5% CO2 in humidified
environment at 37uC.
For tumor model, 2610
5 H22 tumor cells (BALB/c derived) in
50 ml 0.9% sodium chloride sterile saline solution were subcuta-
neously injected to the left flank of BALB/c mice. 20 days later,
when the tumor size reached 969 (mm6mm), the marginal and
central tumor tissues were cut with small surgical scissors for RT-
PCR, Western blot or immunohistochemical analysis.
Analysis of microRNAs by RT-PCR and quantitative
RT-PCR
Total microRNAs were isolated from tumor cell lines using
microRNA isolation kit (Ambion, Austin, TX). Reverse transcrip-
tion primers for miR-199b, 18a, 20b and 155 were designed,
respectively, with RNA mfold version 2.3 server (supporting
information, Figure S4), and its specificity was identified according
to our previous study [35]. 100 ng of enriched microRNA was used
for the cDNA synthesis. A 67-bp cDNA product was amplified by
PCR with primers: miR-199b, 59-CTCACAGTAGTCTGCACA-
39 (sense); miR-18a, 59-GGTAAGGT GCATCTAG TG-39 (sense);
miR-20b, 59-CCCAAAGTGCTCATAGT G-39 (sense); miR-155,
59-CGGTTAATGCTAATTGTG-39 (sense); common antisense
primer, 59-GACTGTTCCTC TCTTCCTC-39.
For real-time PCR, the above primers and the Taqman probe
[6-FAM]TTGCGACTAC ACACACACACACA[BHQ1a-6FAM]
were mixed with TaqManH Universal PCR Master Mix (Applied
Biosystems, Foster City, CA). The reaction mixtures were incubated
at 95uC for 10 min, followed by 40 cycles of 95uC for 15 s and 60uC
for 1 min in Stratagene QRT-PCR instrument.
Identification of the specificity of miR-20b to HIF-1a and
VEGF mRNAs
A 450 bp or 240 bp fragment of 39-UTR of HIF-1a or VEGF
mRNA containing the target sequence (GCACTTT) of miR-20b
was amplified by RT-PCR (HIF-1a, sense 59-CTCTGAG
CTCTATCTGGAAGGTATGTG -39, antisense 59-CCTCAA-
GCTTCAGTTAGTGTTAGACC C-39; VEGF, sense 59-TAAC-
CATGTCACCACCACG-39, antisense 59- CCCAGAAACAA-
CCC TAATC-39). The fragment was designated as HIF-1a or
VEGF 39-UTR, and inserted into pMIR-REPORT
TM luciferase
reporter vector (Sac I and Hind III restriction enzyme sites;
Ambion). Another expressing vector was also constructed by the
insertion of a mutated HIF-1a or VEGF 39-UTR in which the
target sequence of miR-20b was mutated into GCAATTT using
QuikChangeH Site-Directed Mutagenesis Kit (Stratagene). Then,
the recombinant reporter vectors with normal and mutated HIF-
1a or VEGF 39-UTR were cotransfected with miR-20b into CHO
cells, respectively, using TransMessenger
TM Transfection Reagent
(Qiagen). The luciferase assay was performed according to the
manufacturer’s instructions.
Transfection assay
The tranfection assay was performed as described in our
previous study [35]. Briefly, miR-20b (Dharmacon, Lafayette,
CO), miR-20b inhibitor (Ambion, Austin, TX), HIF-1a siRNA
(Invitrogen, Carlsbad, CA), VHL siRNA (Invitrogen), and the
corresponding control oligonucleotides were purchased. HIF-1a-
expressing vector was constructed by inserting HIF-1a cDNA into
pcDNA3.1 vector. For transient transfection, 200 pmoles of
synthesized oligonucleotide or 2 mg of plasmid was mixed with
100 ml of Nucleofector solution (Amaxa, Gaithersburg, MD), and
transfected into 3610
6 tumor cells by electroporation using
Nucleofector instrument. After transfection, the cells were
allowed to recover by incubating for 4 h at 37uC, and then used
for the following assays.
Western blot
Cell lysates (30 mg of total protein) and prestained molecular
weight markers were separated by SDS-PAGE followed by
transfer onto nitrocellulose membranes. The membranes were
blocked in TBST (Tris-buffered saline with 0.5% of Triton X-100)
containing 5% nonfat milk, and probed with the indicated
antibodies. After incubation with the secondary antibody conju-
gated with horseradish peroxidase, membranes were extensively
washed, and the immunoreactivity was visualized by enhanced
chemiluminescence according to the manufacturer’s protocol
(ECL kit, Santa Cruz, Santa Cruz, CA). All antibodies were
purchased from Santa Cruze Biotechnology (Santa Cruz, CA).
HIF-1a and VEGF detection by real time RT-PCR
The cDNA sequences of Hif1a, Vegfa and b-actin genes were
retrieved from NCBI database. The primers were designed with
the Oligo Primer Analysis 4.0 software. Real time RT-PCR was
Regulation HIF-1a by miR-20b
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detected gene was expressed as the relative level to that of b-actin.
Immunohistochemistry
Central or marginal tumor tissues were surgically excised for the
preparation of sections. The sections were fixed by acetone, and
then incubated with 0.1% BSA to block the activity of endogenous
peroxidase. Mouse-anti-human HIF-1a Ab (NB100-131SS, Novus
Biologicals, Littleton, CO), biotinylated anti-mouse IgG (Santa
Cruz), and streptavidin-conjugated horseradish peroxidase (Santa
Cruz) were used for immunohistochemical staining.
Proliferation assay
H22 cells were transfected with miR-20b inhibitor or miR-20b
inhibitor+HIF-1a siRNA or miR-20b or VHL siRNA or control
oligonucleotide for 24 hr. Then the cells were seeded in 96-well
plate (5610
3 per well) for 48 h in normoxia. The proliferation
assay was performed with MTT Cell Proliferation Kit (Roche
Diagnostics, IN) according to the manufacturer’s instructions.
Apoptosis assay
H22 cells were transfected with miR-20b inhibitor or miR-20b
inhibitor+HIF-1a siRNA for 24 hr. Then the cells (1610
6) were
irradiated by UVB (200 J/m
2) or treated with mitomycin C
(MMC, 10 mg/ml)for 12 h. The apoptotic cells were analyzed with
PE Annexin V Apoptosis Detection Kit (BD Biosciences, San
Diego, CA) by flow cytometry.
Statistics
Results were expressed as mean value 6 SD and interpreted by
Students’t test. Differences were considered to be statistically
significant when P,0.05.
Supporting Information
Figure S1 The expressions of miR-18a, 155 and 199b are not
affected by different oxygen concentrations. The H22 and B16
tumor cell lines were treated with different oxygen concentrations.
The expressions of miR-18a, 155 and 199b were detected by real
time RT-PCR. The expression level in the hypoxia groups was
designated as 1.
Found at: doi:10.1371/journal.pone.0007629.s001 (0.40 MB TIF)
Figure S2 The expressions of miR-20a, 106a, 18b, 92-2 and 363
are not affected by different oxygen concentrations. The H22 and
B16 tumor cell lines were treated with different oxygen
concentrations. The expressions of microRNAs were detected by
real time RT-PCR. The expression level in the hypoxia groups
was designated as 1.
Found at: doi:10.1371/journal.pone.0007629.s002 (0.40 MB TIF)
Figure S3 HIF-1a is expressed in the central H22 tumor tissues
but not in marginal tumor tissues. H22 tumor cells were
subcutaneously injected to the left flank of BALB/c mice. When
the tumor size reached 969 mm, central or marginal tumor tissues
were surgically excised for the preparation of sections. The
sections were used for immunohistochemical staining against HIF-
1a. (A) The central tumor tissue was positively stained. (B) The
marginal tumor tissue was negatively stained. (C) The interface of
negative (marginal) and positive (central) staining of HIF-1a.
Found at: doi:10.1371/journal.pone.0007629.s003 (2.19 MB TIF)
Figure S4 Stem-loop structure of reverse transcription primers
for miR-199b, 18a, 20b and 155. The primers were designed with
RNA mfold version 2.3 server. The 39-end sequences of
TAACCAA, CTATCTG, CTACCTG and ACCCCTA were
complementary to the 39-end sequence of miR-199b, 18a, 20b and
155, respectively.
Found at: doi:10.1371/journal.pone.0007629.s004 (0.96 MB TIF)
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